Last reviewed · How we verify
AN2728 Cream, 1%
At a glance
| Generic name | AN2728 Cream, 1% |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2728 Cream, 1% CI brief — competitive landscape report
- AN2728 Cream, 1% updates RSS · CI watch RSS
- Pfizer portfolio CI